Authors: HOLLEMAN F SCHMITT H ROTTIERS R REES A SYMANOWSKI S ANDERSON JH

Citation: F. Holleman et al., REDUCED FREQUENCY OF SEVERS HYPOGLYCEMIA AND COMA IN WELL-CONTROLLED IDDM PATIENTS TREATED WITH INSULIN LISPRO, Diabetes care, 20(12), 1997, pp. 1827-1832

Authors: GLAZER B ZALANI S SYMANOWSKI S UMINGER G ANDERSON J BASTYR E

Citation: B. Glazer et al., CARDIOVASCULAR SAFETY PROFILE OF INSULIN LISPRO (LP), Diabetologia, 40, 1997, pp. 1380-1380

Authors: VIGNATI L ANDERSON JH SZWAST S SYMANOWSKI S

Citation: L. Vignati et al., TWICE-DAILY LISPRO RESULTS IN LESS GLUCOSE VARIABILITY COMPARED TO HUMAN REGULAR INSULIN, Diabetologia, 38, 1995, pp. 191-191

Authors: BRUNELLE RL SYMANOWSKI S ANDERSON JH VIGNATI L

Citation: Rl. Brunelle et al., LESS NOCTURNAL HYPOGLYCEMIA WITH INSULIN-LISPRO IN COMPARISON TO HUMAN REGULAR, Diabetes, 44, 1995, pp. 111-111

Authors: BODICK NC SHANNON HC SYMANOWSKI S

Citation: Nc. Bodick et al., XANOMELINE, A POTENT AND SPECIFIC M1 AGONIST IN THE TREATMENT OF MILDAND MODERATE ALZHEIMERS-DISEASE, Neurobiology of aging, 15, 1994, pp. 190000148-190000148

Authors: ANDERSON J SYMANOWSKI S BRUNELLE R

Citation: J. Anderson et al., SAFETY OF [LYS(B28), PRO(B29)] HUMAN INSULIN ANALOG IN LONG-TERM CLINICAL-TRIALS, Diabetes, 43, 1994, pp. 10000061-10000061